CIRSENTRA Labs
Every biological response changes the capacity for the next one.
How the body meets a demand, rebuilds after it, and becomes ready, or fails to become ready, for the next one. We call the mechanism the Reserve-Setting Cycle. It was discovered at CIRSENTRA Labs and resolved in adult human tissue.
01 · The problem
Medicine identifies causes and measures endpoints. The capacity connecting them has no law.
Five failures every clinician and every laboratory has seen. Each is studied as its own puzzle.
- 01
The same mutation disables one relative and spares another.
- 02
The same drug works in one patient and fails in the next.
- 03
A treatment works, then stops working.
- 04
Recovery looks complete, and relapse follows.
- 05
One local injury produces a multisystem picture.
Each is the same process failing at a different step. Name the step and the puzzle becomes a measurement, then a matched repair.
A 26-year-old runner has a routine viral illness in March. Four days of fever, then back to work. In June she takes the stairs at the office and spends the next three days in bed.
Every rest test is normal. On the tilt table her heart rate climbs past the diagnostic threshold while blood pressure holds. A beta-blocker lowers the standing heart rate and returns not one Saturday. Her training partner cleared the same infection in ten days.
One local virus, whole-body outcome: heart rate, gut, sleep, thinking. Nothing here was unmeasurable. The measurements were taken at rest, and the failure happens after demand.
Same diagnosis, same drug, different outcome is a measurement gap, not a mystery.
02 · The law
Every response runs one cycle. The next response inherits what it leaves.
The same loop runs in a cell and across an organism. Two of its operations, reading and commanding, are the receptor and the switch, mapped molecule by molecule for decades. The cycle draws all eight as one loop, and it closes.
| Muscle cell, after a sprint | Your body, after an infection | |
|---|---|---|
| Reads | spent energy charge, amino acids | what the blood carries: sugar, salt, inflammatory signals |
| Integrator | the lysosomal surface | blood-facing brain sites, the median eminence first among them |
| Command | the mTORC1 and AMPK switch | pituitary and autonomic outputs, the thyroid set point |
The first response measures deployment. The second measures whether it can happen again. What differs between two patients is which operation was rebuilt.
Reserve, restated: what the body can deploy, recover and use again, not what is present at rest.
Training builds it. Sepsis spends it. Chronic infection misroutes it. Cancer takes it.
A normal output can be compensation at rising cost.
03 · What we found
One law, and the architecture it runs on.
The law is the finding. Two objects carry it: the thing a signal has to land on, and the anatomy that reads the body and gives the orders. Three further layers make the architecture measurable in people.
The Competent Receiver
The receptor tests present. The drug has nothing to work on. An enzyme cuts the binding site off the receptor, and it still reads as present.
The real target is the working, reusable receptor, not its name. Cutting is one of five ways the usable population disappears while the label says it is there.
The receiver in full
The architectureThe circumventricular sentinel network
A handful of brain sites face the blood and the spinal fluid directly, read what they carry, set what the rest of the body does, and then read what comes back.
One distributed, high-gain control network, not a universal master. Arrangement, not molecular uniqueness, decides what shared machinery does.
The network in full
The input layer
Pathogen, environmental and host-derived classes converge on the same interfaces. The receiver, not the source name, decides what happens.
The sex-composed receiver
Men and women do not run the same receiver layer. Male interface tissue is already higher on the large splits at age 29. Female clearance architecture is built before birth.
The first reserve
Capacity is constructed before birth. The build programme is set in chromatin before any of it shows up as RNA.
The same blood state produces different disease depending on which node and output branch becomes limiting.
04 · What is already proven
Three predictions, three completed tests, none of them on data we generated.
A framework that only fits its own data is a description. These three tests were fixed in advance and settled in cohorts, autopsy series and a randomised trial run by other groups.
Every demand was met. The rebuild never came.
In cancer cachexia the body meets every demand the tumour creates, pays for them out of its own muscle, and never rebuilds the muscle. The response succeeds. The capacity does not return. In a prospective cohort of 202 patients with pancreatic and periampullary cancer, 144 of them, 71 per cent, were already cachectic at diagnosis.1
The wasting starts before anyone is looking for it. In 714 cases matched to 1,748 controls, skeletal muscle loss is detectable on scans up to 18 months before the clinical diagnosis.2 After diagnosis it keeps costing: patients in the top quartile of muscle loss over two to four months had roughly twice the risk of death of those in the bottom quartile, while fat loss over the same window carried no such association.3 The tumour shrinks and the patient falls.
More of the marker, less of the machinery.
The receiver discovery predicts that abundance and usable competence come apart, because what fails is recovery, not supply. Sudden infant death syndrome is the hardest place to test it: a baby is put to bed healthy and the autopsy shows nothing.
What the autopsy cannot show is the failed rescue. Among 24 infants who died while being monitored at home, 23 produced the hypoxic gasps that begin the rescue, and only 4 ever completed it.4 The machinery starts and does not finish.
Postmortem series then find abundance and function pulling apart in exactly the nuclei that run that rescue. Brainstems in these infants carry roughly twice the count of serotonin neurons alongside lower receptor binding density,5 with serotonin itself down about a quarter and its synthesising enzyme down about a fifth.6 More of the marker, less of the machinery.
Then the direction reversed and the outcome did not. In a later high-risk series, infants born preterm who died of the syndrome showed higher receptor binding than preterm controls, the opposite of the classic result, and still died the same death.7 Abundance in either direction is not the thing that failed.
The architecture located the target. The drug worked.
GDF15, the tissue-stress signal, meets a receptor that sits almost only at one blood-facing hindbrain site. Reading that interface found the target before the trial ran.
In a randomised phase 2 trial, 187 patients with cancer cachexia received a monoclonal antibody against that signal or placebo. Every antibody dose beat placebo on weight at 12 weeks, by 1.22, 1.92 and 2.81 kg, and the highest dose also improved appetite and physical activity.8 What made the target findable was arrangement.
Signal in the blood, receptor at one interface, drug that works. The full chain already exists once, in print. The architecture says where to look for the next one.
Return to baseline is not recovery. Recovery is being able to do it again.
05 · What changes at the bedside
Measure the limiting state. Correct the limiting operation. Prove that the system can do it again.
Find the step that limits
The state the disease walked into, the working receptor population, the interface where the blood is read. Each is a physical thing, measured before the drug is chosen.
Run the matched repair
A cut receptor calls for rebuilding, not a higher dose. A blocked route calls for rerouting. Each limiting step has its own operation, and the measurement picks it.
Ask for the second response
The first response shows what the treatment did. The second shows what the patient recovered. Restoration is proven there, or not at all.
Treat the limiting operation, not the diagnosis alone.
06 · Where this sits
Disease, aging and cancer are not three subjects. They are three readings of one cycle.
The components were known in separate disciplines. The causal object, the mapping from a failed operation to a therapy, and the standard of proof that asks for a second response were not.
Capacity is constructed before birth, deployed and renewed throughout life, progressively narrowed by incomplete reconstruction, which shows up as aging, and selectively appropriated by cancer.
By analogy, and only in this precise sense: the Krebs cycle explained how cells regenerate the intermediates required for metabolism. The Reserve-Setting Cycle explains how physiological systems regenerate the capacity required for the next response.
07 · The laboratory
Medicine can tell you what is in a body. It cannot yet tell you what that body can do twice.
CIRSENTRA Labs works on that gap. The programme is led by Friederike Seiler, with senior collaborators in microbial proteolysis and regenerative medicine.
If it closes, non-response stops being an unexplained outcome and becomes a named lesion with a matched repair. The patient whose tests are normal gets a test that is not normal. Relapse becomes something predicted rather than survived. Aging gets a unit.
Open inputs, original integration. The data that matters is already public. The thinking that connects it is not.
Human data first. Causality in humans, not animals.
Exact denominators. Every number carries its donors, cells or participants, and says whether the analysis is ours.
The direction goes first. Predictions are written down before the data are opened.
Falsifiable by design. Each discovery ships with the result that would end it.
08 · References
Every number on this page, and where it comes from.
The three completed tests run on data generated by other groups. Their papers are listed in full so any claim here can be checked against its source.
- Latenstein AEJ, Dijksterhuis WPM, Mackay TM, et al. Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: a multicenter cohort study. Cancer Medicine. 2020;9(24):9385-9395. doi:10.1002/cam4.3556 ↩
- Babic A, Rosenthal MH, Sundaresan TK, et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nature Communications. 2023;14(1):4317. doi:10.1038/s41467-023-40024-3 ↩
- Babic A, Rosenthal MH, Bamlet WR, et al. Postdiagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer. Cancer Epidemiology, Biomarkers and Prevention. 2019;28(12):2062-2069. doi:10.1158/1055-9965.EPI-19-0370 ↩
- Sridhar R, Thach BT, Kelly DH, Henslee JA. Characterization of successful and failed autoresuscitation in human infants, including those dying of SIDS. Pediatric Pulmonology. 2003;36(2):113-122. doi:10.1002/ppul.10287 ↩
- Paterson DS, Trachtenberg FL, Thompson EG, et al. Multiple serotonergic brainstem abnormalities in sudden infant death syndrome. JAMA. 2006;296(17):2124-2132. doi:10.1001/jama.296.17.2124 ↩
- Duncan JR, Paterson DS, Hoffman JM, et al. Brainstem serotonergic deficiency in sudden infant death syndrome. JAMA. 2010;303(5):430-437. doi:10.1001/jama.2010.45 ↩
- Kinney HC, Folkerth RD, Nelson ME, et al. Serotonergic receptor binding in the brainstem in the sudden infant death syndrome in a high-risk population. PLOS ONE. 2025;20(9):e0330940. doi:10.1371/journal.pone.0330940 ↩
- Groarke JD, Crawford J, Collins SM, et al. Ponsegromab for the treatment of cancer cachexia. New England Journal of Medicine. 2024;391(24):2291-2303. doi:10.1056/NEJMoa2409515 ↩
The science page carries the references for the receiver, the network, the input layer and the developmental work. See them there.
09 · Contact
Two doors into the same room.
The framework is built to be attacked. Each discovery carries the experiment that would refute it, and those experiments are published rather than held.
Read it, then try to break it
Manuscripts, evidence boundaries and the falsifier list per discovery. Written to be reproduced, including where the evidence stops.
The category, and where it stands
Why drugs fail in patients who test positive for the target, what the programme is building against that, and which rung of the evidence ladder it has actually climbed.